Suppression of antitumor T cell immunity by the oncometabolite (R)-2-hydroxyglutarate

Lukas Bunse, Stefan Pusch, Theresa Bunse, +51

Nature Medicine

Cancer ImmunosurveillanceMedicineT-regulatory CellImmunologyTumor Immunity +7

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Michael Platten, Lukas Bunse, Antje Wick, +25

Nature

Tryptophan metabolism drives dynamic immunosuppressive myeloid states in IDH-mutant gliomas

Mirco Friedrich, Roman Sankowski, Lukas Bunse, +34

Nature Cancer

K27M-mutant histone-3 as a novel target for glioma immunotherapy

Katharina Ochs, Martina Ott, Theresa Bunse, +8

OncoImmunology

Dysfunctional dendritic cells limit antigen-specific T cell response in glioma

Mirco Friedrich, Markus Hahn, Julius Michel, +12

Neuro-Oncology

T cell-independent eradication of experimental glioma by intravenous TLR7/8-agonist-loaded nanoparticles

Verena Turco, Kira Pfleiderer, Jessica Hunger, +23

Nature Communications

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Lukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, +16

Neurological Research and Practice

A mutation-specific peptide vaccine targeting <i>IDH1R132H</i> in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16).

Michael Platten, Daniela Schilling, Theresa Bunse, +17

Journal of Clinical Oncology

Inhibition of CD95/CD95L (FAS/FASLG) Signaling with APG101 Prevents Invasion and Enhances Radiation Therapy for Glioblastoma

Jonas Blaes, Carina M. Thomé, Philipp-Niclas Pfenning, +21

Molecular Cancer Research

ATIM-33. NOA-16: A FIRST-IN-MAN MULTICENTER PHASE I CLINICAL TRIAL OF THE GERMAN NEUROONCOLOGY WORKING GROUP EVALUATING A MUTATION-SPECIFIC PEPTIDE VACCINE TARGETING IDH1R132H IN PATIENTS WITH NEWLY DIAGNOSED MALIGNANT ASTROCYTOMAS

Michael Platten, Daniela Schilling, Lukas Bunse, +18

Neuro-Oncology

ImmunodeficienciesImmunologyImmunoeditingImmunotherapeuticsHigh-grade Gliomas +21